
Opinion|Videos|September 19, 2024
WCLC 2024: Analyzing SKIPPirr Data Outcomes for Lung Cancer Advancements
Panelists discuss how the SKIPPirr data outcomes presented at World Conference for Lung Cancer 2024 provide valuable insights into the potential use of amivantamab for advancing lung cancer treatment strategies.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Isatuximab for Multiple Myeloma
2
FDA Approves Perioperative Pembrolizumab Plus Enfortumab Vedotin for MIBC
3
Osimertinib After Chemoradiotherapy Shows Manageable Safety in NSCLC
4
FDA Clears IND for Next-Gen Oncolytic Virus UGN-501 in NMIBC
5








































